Showing 8071-8080 of 20876 results for "".
The Benefits of Physical Therapy for Patients With Diabetes
https://reachmd.com/programs/diabetes-discourse/the-benefits-of-physical-therapy-for-patients-with-diabetes/5677/It is well established that exercise is a critical component in the management of diabetes, but many diabetes patients struggle with exercise. Physical therapists are the "exercise experts" in the guidance of patients' overall care. What are the benefits of physical therapy for patients living withTreatment Modalities for Diabetic Retinopathy
https://reachmd.com/programs/revealing-retina/treatment-modalities-for-diabetic-retinopathy/5626/The standard treatment for proliferative and non-proliferative diabetic retinopathy is laser photocoagulation, but novel methods, including injectable steroids or anti-vascular endothelial growth factor, are also showing promise. What tests can help opthamologists determine the area of leakage in thLandmark ATTR-CM Evidence: Slowing Progression, Not Reversing It
https://reachmd.com/programs/spotlight-attr-cm/landmark-attr-cm-evidence-slowing-progression/67202/Physiogenomics and Diabetes
https://reachmd.com/programs/clinicians-roundtable/physiogenomics-and-diabetes/1911/Is the risk of the glitazones worth the benefit? What if you could predict which patients were susceptible? Dr. Ruaño discusses with host Dr. Leslie Lundt how diabetes patients may benefit from the rapidly growing field of physiogenomics.Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
https://reachmd.com/programs/acc-action-center/effects-of-aldose-reductase-inhibitor-on-exercise-capacity-in-diabetic-cardiomyopathy/24360/ACC.24 - Can treatment with the selective aldose reductase inhibitor AT-001 prevent deterioration of exercise capacity and the onset of HF in patients with diabetic cardiomyopathy? James Januzzi shares the results of ARISE-HF.Keys to Reversing Pediatric Non-Alcoholic Fatty Liver Disease
https://reachmd.com/programs/lipid-luminations/keys-to-reversing-pediatric-non-alcoholic-fatty-liver-disease/4296/Non-alcoholic fatty liver disease (NAFLD) is increasingly common among our young obese patients, a population for which cardiovascular disease and diabetes is a significant concern. Can measured levels of liver fat serve to help us gauge future risk for metabolic consequences in children? Host Dr. LDiabetes in Pregnancy--The Coming Storm
https://reachmd.com/programs/clinicians-roundtable/diabetes-in-pregnancy-the-coming-storm/1792/A storm is coming, but few have heard the forecast. The obesity epidemic in the United States in all age groups will lead to a huge increase in diabetes during pregnancy. Our guest today is Doctor Thomas Moore. He is Professor and Chairman of the Department of Reproductive Medicine, UniversitBreaking Down Biosimilar Insulins: A Look at the Regulatory Process and Impacts
https://reachmd.com/programs/diabetes-discourse/breaking-down-biosimilar-insulins-a-look-at-the-regulatory-process-and-impacts/16062/How might biosimilar insulins transform the way we prescribe treatment for our patients with type 1 and type 2 diabetes?When & How to Screen Patients for Diabetes
https://reachmd.com/programs/diabetes-discourse/when-how-to-screen-patients-for-diabetes/12380/How early should we start screening for diabetes, and what tools are available to us? Dr. John Buse answers this FAQ in honor of Diabetes Alert Day.A Wake-Up Call to Diabetes: Spreading Awareness of Its Seriousness
https://reachmd.com/programs/diabetes-discourse/a-wake-up-call-to-diabetes-spreading-awareness-of-its-seriousness/12378/It can be tempting for patients to undermine the seriousness of diabetes, but Dr. John Buse explains why we need to set the record straight.